#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Factor VIII deficiency Hyperinsulinaemic hypoglycaemia Synovial sarcoma Neuroblastoma Mantle cell lymphoma stage II Pleomorphic liposarcoma Leukocyte adhesion deficiency Idiopathic intracranial hypertension Ependymoma Allogenic stem cell transplantation Leiomyosarcoma recurrent Superficial vein thrombosis Cardiac amyloidosis Rheumatoid arthritis Arrhythmogenic right ventricular dysplasia More trials…

    Learn about Rare Diseases

    Kearns-Sayre syndrome – Treatment Osteosarcoma metastatic – Basic Information Rhabdomyosarcoma Short-bowel syndrome Castleman’s disease Hereditary hypophosphataemic rickets – Treatment SAPHO syndrome Ewing’s sarcoma recurrent – Trials in Disease Osteosarcoma – Treatment Lymphangioma – Diagnostics More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    PF-07868489 Lasmiditan Rigosertib Sodium FLUCLOXACILLIN SODIUM Darolutamide Mavorixafor Alkaline Phosphatase, Bovine Nitrofurantoin RO7268489 Ofatumumab Oritavancin Bupivacaine Hydrochloride Cyclophosphamide Monohydrate Protamine Sulfate Heparin Idarubicin 1,3-BUTYLENE GLYCOL VTX2735 SODIUM ALXN1920 GSKVX000000030918 More therapies…

    Learn about Your Condition

    Mantle cell lymphoma stage III Lymphocytic lymphoma Lymphangioleiomyomatosis Embolism venous Pancreatic carcinoma Inner ear disorder Metastatic malignant melanoma Hypochromic anaemia Rhinitis allergic Systemic scleroderma Orthostatic hypotension Chronic hepatitis C Intermittent claudication Hepatocellular carcinoma Fibromyalgia More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre de Radiothérapie Guillaume le Conquérant

Centre de Radiothérapie Guillaume le Conquérant

61 Rue Denfert Rochereau, Le Havre, 76600, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Squamous cell carcinoma of head and neck
    Investigated drugs:
    • LIGUFALIMAB
    • Ivonescimab
    • Pembrolizumab
    Belgium France Spain

  • Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

    Recruiting

    2 1 1
    Investigated diseases:
    • Squamous cell carcinoma of head and neck
    Investigated drugs:
    • PUCOTENLIMAB
    France

  • Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability

    Recruiting

    2 1 1 1
    Investigated diseases:
    • Rectal cancer
    • Microsatellite instability cancer
    Investigated drugs:
    • Dostarlimab
    France

  • Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

    Recruiting

    2 1 1 1
    Investigated diseases:
    • Squamous cell carcinoma of head and neck
    Investigated drugs:
    • Avelumab
    • Carboplatin
    • Cetuximab
    France

  • Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

    Recruiting

    3 1 1
    Investigated diseases:
    • Metastases to central nervous system
    Investigated drugs:
    • Bevacizumab
    • Prednisolone
    • Sodium Chloride
    France

  • Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Degarelix
    • Leuprorelin Acetate
    • Goserelin
    Belgium France Ireland Spain

  • Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    • Squamous cell carcinoma of head and neck
    Investigated drugs:
    • Durvalumab
    France

  • Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    • Squamous cell carcinoma of head and neck
    Investigated drugs:
    • Cisplatin
    • Nivolumab
    Belgium France Greece Poland Spain

  • Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    • Squamous cell carcinoma of head and neck
    Investigated drugs:
    • Avelumab
    • Cetuximab
    • Cisplatin
    France
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!